Enveric Biosciences Inc (ENVB) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.59 (+0.00%), Market cap $0.00B, 52-week low–high $0.58 ~ $10.33.
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
Financial statements, price targets, institutional (13F) holdings and related news for Enveric Biosciences Inc are updated in real time on BlackAll Trade.
Enveric Biosciences Inc trades at $1.59 (+0.00%). Real-time quotes and charts are available on BlackAll Trade.
Enveric Biosciences Inc has a market cap of about $0.00B.
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the